Jennifer Esposito Appointed to VivaLNK Board of Directors: Over 20 Years of Experience, Esposito Will Advise the Executive Team and Assist in Growth in the Digital Health Space

December 1, 2020

Jennifer Esposito joins the VivaLNK its Board of Directors.

Jennifer Esposito experience lies in the healthcare technology and medical device fields and will provide VivaLNK and its executive team a valuable resource to help direct the company’s strategic growth as it powers the world’s leading RPM (remote patient monitoring) technologies.

Esposito is an executive with over 20 years of experience in the global healthcare IT, medical device, biotechnology, and the health and life sciences industry, currently serving as the VP, Health at Magic Leap. She is currently leading Magic Leap’s Health business unit. Prior to joining Magic Leap, she held leadership roles at GE Healthcare and was more recently the General Manager of Health and Life Sciences at Intel Corporation.

In addition, Esposito has worked in academic medicine and clinical research. In her many years of experience, she has led business development, commercial and service operations, as well as both upstream and downstream strategy and marketing. Her expertise lies in driving business growth and strategies by enabling the adoption of emerging technologies in the healthcare industry.

“I believe we are on the cusp of an acceleration in the transformation of healthcare that we’ve never seen before that will improve health, quality of life, safety and security worldwide,” said Esposito. “Working alongside the incredible executive team at VivaLNK allows my passion for healthcare technology to be fully leveraged. I am honored to have a part in the strategy and continued growth of this innovative company.”

The VivaLNK platform has enabled over 90 healthcare solution partners in 22 countries worldwide, and includes applications for remote and clinical patient monitoring for mobile cardiac telemetry, pharmaceutical clinical trials, and COVID patient monitoring to name a few.

“In order for remote monitoring and telemedicine to reach its full potential, solution providers and clinical or research entities need to be able to depend on the capture and transmission of data, as well as seamlessly implement RPM into existing and new infrastructure. Jennifer not only has deep understanding of this space, but also knows the challenges of our partners well, and I’m thrilled to have her assistance in delivering the highest-quality, turnkey service on the market that ultimately changes the status and adoption of RPM today,” said Jiang Li, CEO of VivaLNK.

SourceVivaLNK

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.